RESEARCH ARTICLE

Retrospective analysis of the use of osteoporosis medication at the presentation of non-vertebral fragility fractures in a predominantly Hispanic population. [version 1; peer review: 1 approved with reservations, 1 not approved]

Annelyn Torres-Reveron¹, Michael Serra-Torres¹,²

¹Research, DHR Health Institute for Research and Development, Edinburg, TX, 78539, USA
²Orthopedic Institute, DHR Health - Doctors Hospital at Renaissance, Edinburg, TX, 78539, USA

Abstract

Background: Despite the high incidence of osteoporosis, many patients at risk of fragility fractures may not initiate treatment due to concerns about side effects, cost or under-diagnosis, such as the case of vertebral fractures. We aimed to identify whether the patient population with non-vertebral fragility fractures where already receiving prophylactic treatment for osteoporosis at presentation within a regional hospital in the southernmost region of the United States. This region is characterized by a high number of patients from Hispanic/Latino heritage (80%) and reduced access to healthcare services. Methods: We conducted a three-year, retrospective cohort study of patients presenting with low impact fractures of the humerus or the shoulder griddle, lower end of radius or ulna and forearm, hip fractures (femoral neck, intertrochanteric/ subtrochanteric), and ankle fractures. Male and female subjects of 50 years or older were included. Demographic data and information on medications reported at fracture presentation were extracted from electronic medical records. Results: We found that 42% of the patients were taking at least one medication to prevent osteoporosis. The predominant combination was vitamin D plus calcium and bisphosphonates. If patients taking only vitamin D plus calcium are excluded, 16.7% of the sample took osteoporosis medications at the fragility fracture presentation. The likelihood of taking osteoporosis medication was increased by age and type of health insurance (Medicare/private insurance), and concomitant diagnosis of impaired gait and mobility. The percentage of the patients taking prophylactic medications for osteoporosis at the time of a fragility fracture was comparable to reported national standards and associated with increased age and health insurance coverage. Conclusion: In a predominantly Hispanic/Latino patient population living in a medically
underserved region, there is substantial recognition and prevention strategies for osteoporosis.

**Keywords**
osteoporosis, prevention, bisphosphonates, calcium, vitamin D, fragility, fractures

**Corresponding author:** Annelyn Torres-Reveron (anne.torres@dhr-rgv.com)

**Author roles:** Torres-Reveron A: Data Curation, Formal Analysis, Investigation, Methodology, Writing – Original Draft Preparation, Writing – Review & Editing; Serra-Torres M: Conceptualization, Data Curation, Supervision, Validation, Writing – Original Draft Preparation, Writing – Review & Editing

**Competing interests:** Dr. Michael Serra-Torres is employed by the Renaissance Medical Foundation, a legal entity of DHR Health that provides medical services. Dr. Annelyn Torres Reveron has no conflicts to declare.

**Grant information:** The author(s) declared that no grants were involved in supporting this work.

**Copyright:** © 2021 Torres-Reveron A and Serra-Torres M. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**How to cite this article:** Torres-Reveron A and Serra-Torres M. Retrospective analysis of the use of osteoporosis medication at the presentation of non-vertebral fragility fractures in a predominantly Hispanic population. [version 1; peer review: 1 approved with reservations, 1 not approved] F1000Research 2021, 10:175 https://doi.org/10.12688/f1000research.51446.1

**First published:** 03 Mar 2021, 10:175 https://doi.org/10.12688/f1000research.51446.1
Introduction

Osteoporosis is a systemic bone disease characterized by a decrease in bone strength reflected by a combination of bone mineral density and bone quality, which includes architecture, turnover, damage accumulation, matrix mineralization, and collagen composition. It affects one in four women and one in eight men over the age of 50 years. It is estimated that 44 million people have either osteoporosis or low bone mass in the United States, representing 55% of the population 50 years and older. The annual cost of osteoporosis fractures in 2018 is estimated at $57 billion dollars and is projected to reach $95 billion by the year 2040. Osteoporosis can be primarily influenced by lifestyle changes and the use of prophylactic bone-forming/preserving agents. Examining the frequency and use of prophylactic medications to prevent osteoporotic/fragility fractures can help design interventions to reduce negative impacts on the elderly.

Osteoporosis leads to fragility fractures most commonly observed in the vertebrae, distal radius, proximal humerus, proximal femur, and ankle that result from minimal trauma, such as a fall from a standing height. While vertebral fragility fractures are the most common manifestation of osteoporosis, only 25% of these fractures are diagnosed, since they are often asymptomatic or mildly asymptomatic. Fragility fractures can lead to loss of functionality, pain, limitation of activities of daily living (ADLs), increased morbidity, disability, and significant adverse effect on the quality of life. These consequences present a high burden on healthcare systems due to increased hospitalizations, surgeries, utilization requirements (e.g., rehabilitation/physical therapy, home care, nursing), and medical costs. A study comparing the hospitalization burden due to fragility fractures in women 55 years or over found that annual cost for fragility fracture admissions was more significant than the cost of myocardial infarction, stroke, or breast cancer. It is estimated that the global number of fragility fractures was nine million annually in 2000, including 1.6 million hip fractures, 1.7 million wrist fractures, and 1.4 million spine fractures. It is predicted that this number will continue to increase due to the changes in life expectancy and to change demographics globally. Moreover, by the year 2050, it is estimated that 70% of all patients with hip fractures will be located in Asia, Latin America, and the Middle East.

In 2020, the United States population of patients over the age of 50 years old is between 13–20%. This number is projected to increase to 28–40% by 2050. Hispanics, according to the 2000s United States-Census, represent the largest minority group at 12.5% of the total population, and this ethnic group is anticipated to increase to 25% by the year 2050. It is estimated that 70% of all patients with hip fractures will be located in Asia, Latin America, and the Middle East.

Chronic conditions, social clinical and medical insurance status, and non-modifiable risk factors: race, age, sex, dementia, past medical and family history of fractures. Understanding the interaction of modifiable and non-modifiable factors in Hispanics is crucial to design and implement appropriate prevention programs for osteoporosis.

Osteoporosis continues to be under-recognized and under-treated despite its massive economic cost and impact on morbidity and mortality. The viability of health systems payer (insurance) and economic conditions has been related to quality in health care provided in Latin American regions. A recent study showed that in four countries from Latin America, the baseline number of postmenopausal women using any type of osteoporosis medication was 70.9%, contrasting with that for the East Asia (63.3%) and Middle East (19.9%) sub-cohorts before any intervention occurred.

Most medications for treatment of osteoporosis work by either decreasing bone resorption, (bisphosphonates, selective estrogen receptor modulators, Denosumab- RANK ligand inhibitors) or increasing bone formation (recombinant parathyroid hormone). Using a patient cohort from the southernmost border of the United States composed of approximately 80% Hispanics, we aim to recognize whether the population presenting with non-vertebral fragility fractures is receiving prophylactic treatment for such condition. Based on prior reports from Latin America, we hypothesized that use of prophylactic medications for osteoporosis is significantly lower in our cohort than previously reported national studies in the United States. Our target is to improve the knowledge of osteoporosis treatment use in the Hispanic population at presentation with a fragility fracture and increase early interventions in communities at risk.

Methods

Ethics statement

The study conformed to the Declaration of Helsinki and the U.S. Federal Policy for the Protection of Humans Subjects and was approved by the Institutional Review Board; protocol number 1542366-6. This retrospective study received approval on February 3, 2020, by the DHR Health Institute for Research and Development IRB under the expedited mechanism of review. A full waiver of consent to participate was submitted and approved by the IRB, specifying the retrospective nature of the study and the age of the participants to be included. All data was collected and analyzed de-identified.

Study design and setting

This is a three-year, retrospective cohort study of patients from a single hospital, Level 2 Trauma Center in South Texas. The retrospective period of chart review was set from January 1, 2017, to December 31, 2019.

Participants

Male and female participants 50 years and older presenting to any of the clinics or emergency rooms at our health system were included in the study. The electronic medical record at the hospital links with that of primary care providers and other
clinics within the health system (including urgency room, orthopedic, endocrinology, and radiology depts., etc.), allowing for prescriptions of multiple providers to be captured in the patient’s medical record. The following types of fractures were included: upper end of the humerus or the shoulder girdle, lower end of radius or ulna and forearm, displaced or non-displaced femoral neck, intertrochanteric/ subtrochanteric fractures, the lower end of tibia, medial malleous, lateral malleous, or lower leg. Patients were excluded from the study if the onset of the injury or presentation was outside the study period, if the fracture was already treated at another institution (e.g., referred to a rehabilitation hospital), or if the fracture was nonunion. Additional exclusion criteria were based on the mechanism of injury: fractures produced as a result of projectiles, motor vehicle accidents, or falls from a height higher than one meter were excluded from the cohort. Fractures due to diagnosed/ documented cancer were excluded as well. Fragility fractures of the vertebrae (as defined by the International Classification of Disease-10 as M80.08) were initially considered in this study. However, the incidence of such fractures, as documented in the medical records, was lower than any of the other types of fragility fractures included herein. Therefore, fractures of the vertebrae were underdiagnosed, similar to what has been previously reported for this type of injuries\(^{21,22}\). To reduce the introduction of information bias, these fractures were purposefully excluded from data extraction or analysis\(^3\).

### Variables
The demographic variables included were age, sex, ethnicity, body mass index, date of arrival, presentation site, and health insurance or self-pay. From the medical record, we obtained the onset of the injury, the primary diagnosis and secondary diagnosis, the mechanism of injury, treatment received and date, intensive care unit (ICU) usage, comorbidities, home medications use at the time of presentation, zip code of primary residency, discharge disposition, and history of prior dual-energy X-ray absorptiometry (DXA) scan. The type and number of drugs for osteoporosis treatment and prevention were classified based on their mechanism of action: bisphosphonates, RANK ligand inhibitors, estrogen, selective estrogen receptor modulators, sclerostin inhibitor, parathyroid hormone analog, calcium, and vitamin D. As a surrogate for patient’s mortality at six months and 12 months, we used the last known reported activity at the hospital, regardless of services requested. In some cases, detailed notes from clinicians indicated the patient’s status.

### Data source/measurements
Patients meeting inclusion criteria were identified via an electronic report from the hospital trauma registry, and the business intelligence department at the hospital system. The trauma registry is populated from information directly extracted from the patient’s medical record and is used for purposes of quality improvement and trauma level certification by the American College of Surgeons. The first author has unlimited access to generate reports from the trauma registry using the software DI Report Writer (DI Data Management System) and the second author has unlimited access to the electronic medical record used in the hospital. Home medications, diagnosis of osteoporosis and occurrence of a DXA scan were not part of the trauma registry, and were extracted via a report from the hospital business intelligence department. The files were filtered and processed using the Pandas package for Python (https://pandas.pydata.org/). Each medication was classified using string processing of its generic and the brand names as published by the National Osteoporosis Foundation (https://www.nof.org/patients/treatment/medicationadherence/), plus calcium and vitamin D. The resulting classifications were then analyzed for frequencies. The process was verified by the first author to ensure that no data was missing and all possible medication classes (grouped by their mechanism of action) were accounted. All presented information was part of the participant’s standard of care as documented in their medical record, and no data were collected directly from the patient. The orthopedic surgeon (second author) provided oversight of the data collection process and designed the group comparisons.

### Codes and Algorithms
The fractures were identified using the International Classification of Diseases 10\(^{th}\) revision (ICD10) as follows: fractures of the upper end of the humerus (S42.2) or the shoulder girdle (S42.9); fractures of the lower end of radius (S52.5), lower end of ulna (S52.60), fractures of the forearm (S52.9), displaced or non-displaced femoral neck, intertrochanteric/ subtrochanteric fractures (S72.0, S72.1, and S72.2), fracture of the lower end of tibia, medial malleous, lateral malleous or lower leg (S82.3, S82.5, S82.6, and S82.8). All modifiers to the above fractures based on the ICD10 were also included. Once all patients presenting with these fractures were identified, data was further filtered to retain only those patients who were older than 50 years of age at the time of injury. Subsequently, participants were excluded if the mechanism of injury was other than a fall from a height greater than one meter. Both exclusion rules were done using the parameters reported in the trauma registry. The exclusion criteria was validated by randomly verifying 20 patients from each ICD10 classification (S42, S52, S72, S82) using the clinical notes documented in the patient’s medical record.

### Statistical methods
Descriptive statistics were used for the entire study population. Frequencies and column percentages were used to summarize categorical variables. The normal distribution of continuous variables was measured using the Shapiro-Wilk goodness-of-fit test. Non-normally distributed variables were analyzed using the Wilcoxon test, and normally distributed variables were analyzed using the Student t-test for independent samples. Chi-square or Fisher exact tests were used for categorical variables. Multinomial regression analyses were used to explore the changes in medication across injury types, taking into consideration the age and sex of the patients. The statistical analyses were two-sided and conducted using JMP 15.0 (SAS Institute, Inc, Carry, NC, USA). The statistical significance was set at \(p < 0.05\).

An earlier version of this article can be found on bioRxiv (doi: https://doi.org/10.1101/2020.12.24.424289).
Results

Participants

A total of 864 cases of non-vertebral fractures in patients older than 50 years of age were identified: 121 shoulder cases, 230 wrist cases, 297 hip cases, and 216 ankle cases. Most of the excluded clinical cases were due to the mechanisms of high energy injuries: pedestrian-MVA injuries, motor vehicle accidents, and falls from a height greater than one meter. A handful of cases were excluded due to inaccurate coding of fracture. The final cohort consisted of 719 patients.

Demographic characteristics and medication use

Table 1 describes the number of cases included in each cohort grouped by the site of injury. Patients were predominantly female (≥60%), except for shoulder injuries, where 16% of the cases were females. 81% of the patients self-reported as Hispanic/Latino ethnicity, which is representative of the demographic distribution for the region. The average age of the cohort was 74.03 ± 11.90 years. Patients with ankle injuries were the youngest in the cohort, with an average age of 66.72 ± 11.08. The length of stay in the hospital was highest for hip injuries (3.19 ± 5.05 days) and lowest for wrist injuries (0.32 ± 1.87 days). Only 62 patients (8.6%) had a prior diagnosis of osteoporosis. The highest percentage of prior diagnosis was in patients with hip fractures and the lowest was in patients with ankle fractures (13.1% and 5.3%, respectively). Of the patients with prior diagnosis, 51 (82%) were taking osteoporosis medications, while 11 (17.7%) were not taking any osteoporosis medication. 98% of the patients diagnosed with osteoporosis were female, while only one patient was male. 10% of the cohort (72 patients) had a dual-energy X-ray absorptiometry (DXA) scan, from which 66 patients were female, and only six were male. The highest percentage of patients who received a DXA presented with shoulder fractures (12%). The following three classes of medications were not reported being used by any of the participants: sclerostin inhibitor (Romosozumab), parathyroid hormone analog (Teriparatide), and parathyroid hormone-related protein analog (Abaloparatide); hence these were not included in any of the results tables.

Patients were stratified based on the number of medications for osteoporosis they were taking (zero to four). 42% of the patients, regardless of the fracture site, were taking at least one medication, while 58% were not taking any medication for osteoporosis at the time of fracture (Table 2). Within those taking medications, the vast majority took one or two. The most common medications were a combination of Vitamin D plus calcium and bisphosphonates (Table 3). Other than Vitamin D plus calcium, only 16.7% were on medications for osteoporosis. The percentage of patients taking medications also varied by fracture site, with the highest percentage of patients in the hip fracture group (58.9%) and the lowest in the ankle fractures group (27.8%). Patients who had Medicare as the principal payer constituted 70% of the cohort, which is expected due to the age group. The type of health insurance influenced whether the patients took osteoporosis medication (X²= 66.78, d.f.= 4, p< 0.001; Figure 1). The odds of taking osteoporosis medication for patients on Medicare compared to self-pay was 6.84 (95% CI: 2.62 to 17.85). The odds were even higher for patients in Medicare than other payment types grouped together (government, charity, indigent): 11.76 (95% CI: 3.56 to 38.86). However, the odds of taking osteoporosis medications for those patients in Medicare compared to private insurance was similar at 1.49 (95% CI: 0.55 to 4.08; Figure 1). Besides a documented diagnosis for osteoporosis, 10 other comorbidities were collected from the patient charts: hypertension, obesity, impaired gait or mobility, diabetes, hyperlipidemia, osteoarthritis, other cardiovascular conditions besides hypertension, thyroid-related disease, renal disease, and any cancer. The three most frequent comorbidities in the cohort were: hypertension (59.1%), obesity (47.7%), and impaired gait or mobility (45.2%). Neither hypertension nor obesity influenced whether the patient was taking any type of osteoporosis medication. However, patients with impaired gait or mobility and patients with thyroid-related disease had an increased odds ratio of receiving osteoporosis medications at 2.56 (95% CI, 1.80 to 3.65) and 5.33 (95% CI, 3.04 to 9.36), respectively. The remaining comorbidities did not influence osteoporosis medication patterns.

Table 1. Demographics and baseline characteristics.

<table>
<thead>
<tr>
<th>Variable</th>
<th>All</th>
<th>Wrist</th>
<th>Shoulder</th>
<th>Hip</th>
<th>Ankle</th>
</tr>
</thead>
<tbody>
<tr>
<td>N. of patients</td>
<td>719</td>
<td>197</td>
<td>99</td>
<td>236</td>
<td>187</td>
</tr>
<tr>
<td>Gender female, n (%)</td>
<td>550 (76.5)</td>
<td>160 (81.2)</td>
<td>16 (16.2)</td>
<td>165 (69.9)</td>
<td>142 (75.9)</td>
</tr>
<tr>
<td>Hispanic/Latino ethnicity, n (%)</td>
<td>588 (81.8)</td>
<td>174 (88.3)</td>
<td>80 (80.8)</td>
<td>181 (76.7)</td>
<td>153 (81.8)</td>
</tr>
<tr>
<td>Age, mean (SD)</td>
<td>74.03 (11.90)</td>
<td>72.07 (11.41)</td>
<td>75.6 (9.42)</td>
<td>80.80 (9.83)</td>
<td>66.72 (11.08)</td>
</tr>
<tr>
<td>LOS, mean (SD)</td>
<td>1.38 (3.57)</td>
<td>0.32 (1.87)</td>
<td>1.06 (2.49)</td>
<td>3.19 (5.05)</td>
<td>0.37 (1.87)</td>
</tr>
<tr>
<td>Prior osteoporosis Dx, n (% of total)</td>
<td>62 (8.6)</td>
<td>13 (6.6)</td>
<td>8 (8.0)</td>
<td>31 (13.1)</td>
<td>10 (5.3)</td>
</tr>
<tr>
<td>Prior DXA, n (% of total)</td>
<td>72 (10.0)</td>
<td>21 (10.7)</td>
<td>12 (12.1)</td>
<td>20 (8.5)</td>
<td>19 (10.2)</td>
</tr>
</tbody>
</table>

N, number; Dx, diagnosis; SD, standard deviation; DXA, dual energy X-ray absorptiometry, LOS, length of stay.
### Table 2. Number and type of medications reported at fragility fracture presentation.

<table>
<thead>
<tr>
<th>Variable</th>
<th>All</th>
<th>Wrist</th>
<th>Shoulder</th>
<th>Hip</th>
<th>Ankle</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Number of osteoporosis medications reported at presentation, n (% of column)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>None</td>
<td>411 (57.1)</td>
<td>125 (63.4)</td>
<td>54 (54.5)</td>
<td>97 (41.1)</td>
<td>135 (72.1)</td>
</tr>
<tr>
<td>1</td>
<td>157 (21.8)</td>
<td>42 (21.3)</td>
<td>29 (29.3)</td>
<td>56 (23.7)</td>
<td>30 (16.0)</td>
</tr>
<tr>
<td>2</td>
<td>111 (15.4)</td>
<td>21 (10.7)</td>
<td>13 (13.1)</td>
<td>59 (25.0)</td>
<td>18 (9.6)</td>
</tr>
<tr>
<td>3</td>
<td>34 (4.7)</td>
<td>7 (3.5)</td>
<td>2 (2.0)</td>
<td>21 (9.2)</td>
<td>4 (2.1)</td>
</tr>
<tr>
<td>4</td>
<td>6 (0.8)</td>
<td>2 (1.0)</td>
<td>1 (1.0)</td>
<td>3 (1.3)</td>
<td>0</td>
</tr>
<tr>
<td><strong>Number of osteoporosis medications reported at presentation, excluding calcium and vitamin D n (% of column)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>None</td>
<td>599 (83.3)</td>
<td>164 (83.3)</td>
<td>85 (85.9)</td>
<td>190 (85.5)</td>
<td>160 (85.6)</td>
</tr>
<tr>
<td>1</td>
<td>107 (14.9)</td>
<td>31 (15.7)</td>
<td>10 (10.1)</td>
<td>42 (17.8)</td>
<td>24 (12.8)</td>
</tr>
<tr>
<td>2</td>
<td>12 (1.7)</td>
<td>2 (1.0)</td>
<td>4 (4.0)</td>
<td>3 (1.3)</td>
<td>3 (1.6)</td>
</tr>
<tr>
<td>3</td>
<td>1 (0.14)</td>
<td>0</td>
<td>0</td>
<td>1 (0.4)</td>
<td>0</td>
</tr>
<tr>
<td><strong>Medication class reported at presentation, excluding calcium and vitamin D, n (% of column)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Biphosphonates</td>
<td>90 (68.2)</td>
<td>24 (61.5)</td>
<td>12 (9.1)</td>
<td>40 (30.3)</td>
<td>14 (10.6)</td>
</tr>
<tr>
<td>Estrogen</td>
<td>19 (14.4)</td>
<td>8 (20.5)</td>
<td>2 (11.1)</td>
<td>3 (5.8)</td>
<td>6 (26.1)</td>
</tr>
<tr>
<td>Denosumab</td>
<td>11 (8.3)</td>
<td>4 (10.3)</td>
<td>1 (5.6)</td>
<td>5 (9.6)</td>
<td>1 (4.3)</td>
</tr>
<tr>
<td>Raloxifene</td>
<td>6 (4.5)</td>
<td>2 (5.1)</td>
<td>2 (11.2)</td>
<td>1 (1.9)</td>
<td>1 (4.3)</td>
</tr>
<tr>
<td>Calcitonin</td>
<td>6 (4.5)</td>
<td>1 (2.6)</td>
<td>1 (5.6)</td>
<td>3 (5.8)</td>
<td>1 (4.3)</td>
</tr>
</tbody>
</table>

### Table 3. Combinations of osteoporosis medications used from the most frequent to the least frequent.

<table>
<thead>
<tr>
<th>Drug 1</th>
<th>Drug 2</th>
<th>Drug 3</th>
<th>Drug 4</th>
<th>N</th>
<th>% Total</th>
<th>% Meds</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vitamin D</td>
<td></td>
<td></td>
<td></td>
<td>110</td>
<td>15.3%</td>
<td>35.7%</td>
</tr>
<tr>
<td>Vitamin D</td>
<td>Calcium</td>
<td></td>
<td></td>
<td>78</td>
<td>10.8%</td>
<td>25.3%</td>
</tr>
<tr>
<td>Biphosphonates</td>
<td></td>
<td></td>
<td></td>
<td>34</td>
<td>4.7%</td>
<td>11.0%</td>
</tr>
<tr>
<td>Vitamin D</td>
<td>Calcium</td>
<td>Biphosphonate</td>
<td></td>
<td>21</td>
<td>2.9%</td>
<td>6.8%</td>
</tr>
<tr>
<td>Vitamin D</td>
<td>Biphosphonates</td>
<td></td>
<td></td>
<td>18</td>
<td>2.5%</td>
<td>5.8%</td>
</tr>
<tr>
<td>Estrogen</td>
<td></td>
<td></td>
<td></td>
<td>11</td>
<td>1.5%</td>
<td>3.6%</td>
</tr>
<tr>
<td>Biphosphonates</td>
<td>Calcium</td>
<td></td>
<td></td>
<td>6</td>
<td>0.8%</td>
<td>1.9%</td>
</tr>
<tr>
<td>Vitamin D</td>
<td>Calcium</td>
<td>Denosumab</td>
<td></td>
<td>4</td>
<td>0.6%</td>
<td>1.3%</td>
</tr>
<tr>
<td>Vitamin D</td>
<td>Calcium</td>
<td>Biphosphonate</td>
<td>Estrogen</td>
<td>2</td>
<td>0.3%</td>
<td>0.6%</td>
</tr>
<tr>
<td>Vitamin D</td>
<td>Calcium</td>
<td>Biphosphonate</td>
<td>Denosumab</td>
<td>2</td>
<td>0.3%</td>
<td>0.6%</td>
</tr>
<tr>
<td>Vitamin D</td>
<td>Calcium</td>
<td>Biphosphonate</td>
<td>Calcitonin</td>
<td>2</td>
<td>0.3%</td>
<td>0.6%</td>
</tr>
<tr>
<td>Vitamin D</td>
<td>Calcium</td>
<td>Calcitonin</td>
<td></td>
<td>2</td>
<td>0.3%</td>
<td>0.6%</td>
</tr>
</tbody>
</table>
### Table

<table>
<thead>
<tr>
<th>Drug 1</th>
<th>Drug 2</th>
<th>Drug 3</th>
<th>Drug 4</th>
<th>N</th>
<th>% Total</th>
<th>% Meds</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vitamin D</td>
<td>Calcium</td>
<td>Estrogen</td>
<td></td>
<td>2</td>
<td>0.3%</td>
<td>0.6%</td>
</tr>
<tr>
<td>Calcium</td>
<td>Estrogen</td>
<td></td>
<td></td>
<td>2</td>
<td>0.3%</td>
<td>0.6%</td>
</tr>
<tr>
<td>Calcium</td>
<td>Denosumab</td>
<td></td>
<td></td>
<td>2</td>
<td>0.3%</td>
<td>0.6%</td>
</tr>
<tr>
<td>Calcium</td>
<td>Raloxifene</td>
<td></td>
<td></td>
<td>2</td>
<td>0.3%</td>
<td>0.6%</td>
</tr>
<tr>
<td>Raloxifene</td>
<td></td>
<td></td>
<td></td>
<td>2</td>
<td>0.3%</td>
<td>0.6%</td>
</tr>
<tr>
<td>Vitamin D</td>
<td>Calcium</td>
<td>Raloxifene</td>
<td></td>
<td>1</td>
<td>0.1%</td>
<td>0.3%</td>
</tr>
<tr>
<td>Vitamin D</td>
<td>Calcitonin</td>
<td>Biphosphonate</td>
<td></td>
<td>1</td>
<td>0.1%</td>
<td>0.3%</td>
</tr>
<tr>
<td>Vitamin D</td>
<td>Denosumab</td>
<td>Biphosphonate</td>
<td></td>
<td>1</td>
<td>0.1%</td>
<td>0.3%</td>
</tr>
<tr>
<td>Vitamin D</td>
<td>Estrogen</td>
<td>Biphosphonate</td>
<td></td>
<td>1</td>
<td>0.1%</td>
<td>0.3%</td>
</tr>
<tr>
<td>Estrogen</td>
<td>Calcitonin</td>
<td>Biphosphonate</td>
<td></td>
<td>1</td>
<td>0.1%</td>
<td>0.3%</td>
</tr>
<tr>
<td>Biphosphonates</td>
<td>Denosumab</td>
<td></td>
<td></td>
<td>1</td>
<td>0.1%</td>
<td>0.3%</td>
</tr>
<tr>
<td>Vitamin D</td>
<td>Denosumab</td>
<td></td>
<td></td>
<td>1</td>
<td>0.1%</td>
<td>0.3%</td>
</tr>
<tr>
<td>Vitamin D</td>
<td>Raloxifene</td>
<td></td>
<td></td>
<td>1</td>
<td>0.1%</td>
<td>0.3%</td>
</tr>
</tbody>
</table>

*% of Total* refers to the total number of patients included in the study (n= 719); % Meds refers to the total number of patients that were taking medications at fracture presentation (n= 308).

### Figure 1

**Figure 1. Percent of patients taking osteoporosis medications by the type of health insurance or payer (vitamin D plus calcium excluded).** Patients who took medications for osteoporosis ("YES" column) had predominantly Medicare or Medicaid. However, at ages younger than 66, many patients were not taking any medications for osteoporosis ("NO" column) irrespective of the high incidence of private insurance. Data from 24.
Outcomes-based on sex and age group

To further understand osteoporosis medication use patterns across sex, data were stratified based on three age groups: 50–65, 66–83, and 83 years and older (Figure 2). The age groups were constructed using the 25th quartile (65 years) and 75th quartile (83 years) for age. Regardless of fracture site and age, females had a significantly higher odds of taking osteoporosis medications than males: 1.77 (95% CI, 1.21 to 2.58). Patients presenting with hip fractures at any age had the highest odds of taking osteoporosis medication compared to patients with fractures in any other body area: 2.66 (95% CI, 1.94 to 3.68). The odds for patients presenting with shoulder fractures to be on osteoporosis medications was very similar to other fractures at 1.13 (95% CI, 0.73 to 1.73). The older the patient, the higher the probability of patients taking osteoporosis medications. The odds for osteoporosis medication use in patients in the 84 years and older group compared to patients in the 50–65 years group were 4.92 (95% CI, 3.12 to 7.82). Similarly, patients in the 66–83 years group had odds of taking medication of 3.75 (95% CI, 2.29 to 5.19) than the younger group.

Discussion

Contrary to our hypothesis, the use of medications to prevent osteoporosis in patients that present non-vertebral fragility fractures were comparable to previously reported national averages. Within the set of patients taking osteoporosis medications, the use of calcium, vitamin D, and bisphosphonates constituted more than 80% of the consumption. When calcium and vitamin D were not considered, the percent of patients on osteoporosis medications dropped by 25% (from 42 to 16.7%) but remained above the national averages of 10% for years 2010–2011. Females were more likely to take osteoporosis medications, and this probability increased with age. In our population, the number of male patients presenting with fractures and treated with osteoporosis medications was very low. This finding is similar to previous reports, which is partially explained due to underdiagnosed and under-treatment of males for osteoporosis. To our knowledge, this is the first time that a study identifies the use of medications for osteoporosis within the southernmost region of the United States, with a high prevalence of Hispanic/Latino heritage.

When we examine socioeconomic status and self-reported race/ethnicity, reports have shown that individuals at an extreme socioeconomic disadvantage are very vulnerable to relatively low bone mineral density. The Rio Grande Valley (southernmost Texas, USA) population is well documented to have low socioeconomic status with an individual median income of only $22,302 dollars (median for the state of Texas, USA: $30,596). The Rio Grande Valley is also classified as a

![Figure 2. Percent of patients using osteoporosis medications sub-divided by sex and age groups.](image-url)

Zero (0) value in the figure represents patients that were not taking any medications for osteoporosis. It is evident that males were using fewer medications (if any) than females and this was obvious for hip fractures. Females with shoulder fractures had the largest increase across age groups in the percentage of patients taking medications. Please refer to the Results sections for odds ratios. Data from 24.
medically underserved population with a prevalence of 30% for uninsured/underinsured patients\(^9\). Despite these well documented socioeconomic conditions, the use of osteoporotic medication was not lower than the national average. However, it is essential to consider that vitamin D and calcium, which can be obtained at a low cost and without prescription, were the predominant medications used in our population. Within our cohort, patients taking medications for osteoporosis were older and had a higher prevalence of comorbidities than patients not taking medications for osteoporosis. The need for closer multidisciplinary medical treatment for patients with increased age and multiple comorbidities produce more medical interventions and closer monitoring, allowing for identification of the patient is at risk of osteoporosis and medical treatment interventions.

A study looking at bone turnover in Mexican Americans who also have type 2 diabetes found lower bone turnover in men with diabetes and poor glycemic control\(^10\); hence, screening for osteoporosis in Mexican Americans to prevent fractures should be highly considered\(^1\). Native Americans, White and Hispanic women remain among the highest for fracture risk than other ethnic groups (Black, Asian)\(^12\). Given that the Rio Grande Valley population is medically underserved and has a high prevalence of type 2 diabetes, we believe that there could be an increased risk of osteoporosis-related fractures in our community. However, this information has never been collected nor reported.

We observed a discrepancy for prior osteoporosis diagnosis within our data with the number of patients taking the medications. This discrepancy might be produced by a lack of proper documentation within the medical records or simply by the retrospective nature of the data. It is possible that patients might have been diagnosed at a primary care facility not associated with our hospital system; thus, documentation of DXA scans or diagnosis is not within our system’s electronic medical record. However, it should be noted that in the mid-nineties, the use of bone mineral density scans for osteoporosis was not recommended\(^8\), but this view has been challenged, and DXA remains the “gold standard” for osteoporosis diagnosis\(^14,32\). An additional possibility to consider is that the patients initiate the reported use of calcium and vitamin D on their own, as part of a multi-vitamin regime, or only as a physician’s recommendation due to their advanced age. The latter is supported by a previous study indicating that for Hispanics, information regarding medication use and adherence is more readily received from the doctor than from any other source of information: “the doctor is still king”\(^9\). Future prospective studies should address the process of diagnosis and reporting, both by primary care and specialty doctors.

**Study limitations**

Retrospective cohort studies provide a quick estimate when no previous data on the topic exist, especially for specific populations, but it also carries a series of limitations. Information regarding the length that the patients have been taking the medication was not collected, nor the effectiveness of such medications. While the number of patients taking medications in the current study is not suggestive of underreporting, it is always possible that patients are taking calcium plus vitamin D as part of their regular multi-vitamins but do not consider vitamins as “medicine” or “treatment.” Hence the possibility of underreporting is impossible to rule out. An attempt to verify previous fracture history was initiated, but we ruled out acquiring this information given that our region has three large hospitals. The possibility of patients seeking care for a prior fracture at a different facility is high. Thus, future studies should consider a multi-institutional design, allowing the recording of this type of information. We acknowledge an intrinsic bias in the study design by selecting patients that already present with a fracture. However, the presence of a fragility fracture is one of the critical factors for the diagnosis of osteoporosis\(^7\). Based on the new practice guidelines for endocrinologists, the current patient population would fall on the very high-risk group based on the presence of a fracture within the previous 12 months\(^8\). Despite the limitations, the current study sets the stage for designing prospective interventions in high-risk groups for osteoporotic fractures.

**Conclusions**

Osteoporosis continues to be an underdiagnosed and undertreated disease. In our cohort, despite the high use of prophylactic medication among the most elderly patients, the usage of medications in the younger population continues to be minimal. Within the male population, the usage and diagnosis of osteoporosis continue to be almost nonexistent. Despite slightly higher use of prophylactic medication than national standards, the percentage of patients taking medication still falls under desired levels, especially considering that only 16% of the patients took medication once vitamin D plus calcium were removed from the comparison. It is essential to recognize there is still significant work to promote consciousness, improve diagnoses, and encourage early use of prophylactic medications.

**Data availability**

**Underlying data**

Zenodo: Retrospective analysis of the use of osteoporosis medication at the presentation of non-vertebral fragility fractures in a predominantly Hispanic population. https://doi.org/10.5281/zenodo.4526306\(^34\).

The project contains the following underlying data:

- Full data oseto-de-identified.csv (This is a de-identified data set including 719 patients older than 50 years of age. The patients have a fragility fracture of the hip, shoulder, wrist and ankle. Comorbidities and medications taken at the time of presentation are documented.)

**Reporting guidelines**

Zenodo: STROBE checklist for “Retrospective analysis of the use of osteoporosis medication at the presentation of non-vertebral fragility fractures in a predominantly Hispanic population”. http://doi.org/10.5281/zenodo.4557854\(^37\).

Data are available under the terms of the Creative Commons Attribution 4.0 International (CC BY 4.0).
Acknowledgments

We acknowledge the contributions of DHR Health employees from the Quality Department in some aspects of data extraction, and an intern from the Education Department for providing help with data mining. We appreciate the valuable comments on the manuscript from Dr. Lisa Trevino and Mr. Peter Roberge from DHR Health Institute for Research and Development.

References


Open Peer Review

Current Peer Review Status: ✗ ❓

Version 1

Reviewer Report 28 July 2021

https://doi.org/10.5256/f1000research.54616.r89853

© 2021 Chin K. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Kok-Yong Chin
Department of Pharmacology, Faculty of Medicine, Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia

The authors reported the use of osteoporosis medications in Hispanic populations with low sociodemography admitted for fragility fracture in a single centre in USA. The data are valuable in providing insights into osteoporosis preventive practices among this population. The manuscript is well written and all limitations were acknowledged by the authors. I only have minor comments on the manuscript.

Title: osteoporosis medications.

Abstract: The predominant combination was vitamin D plus calcium and bisphosphonates - please provide the percentage.

Introduction:
- The prevalence of osteoporosis as indicated in ref 2 is quite outdated. Please replace with updated data.
- The annual cost of osteoporosis fractures - are the authors referring to global or US data?
- The entire paragraph 2 can be summarised and integrated into paragraph 1.

Results:
- "121 shoulder cases, 230 wrist cases, 297 hip cases, and 216 ankle cases" - please also provide the percentage.
- "81% of the patients" - please do not start the sentence with numerical.
- Generic drug names such as romosozumab, teriparatide and abaloparatide should not be capitalised.
Please provide the percentage for the following statement "Within those taking medications, the vast majority took one or two. The most common medications were a combination of Vitamin D plus calcium and bisphosphonates".

Subheading: "Outcomes-based on sex and age group" should be modified as outcomes may be misinterpreted as "fracture outcomes". It is actually analysis based on sex and age group.

Discussion: "... in patients that present non-vertebral fragility fractures" - replace 'that' with 'who'.

Is the work clearly and accurately presented and does it cite the current literature? Yes

Is the study design appropriate and is the work technically sound? Yes

Are sufficient details of methods and analysis provided to allow replication by others? Yes

If applicable, is the statistical analysis and its interpretation appropriate? Yes

Are all the source data underlying the results available to ensure full reproducibility? Yes

Are the conclusions drawn adequately supported by the results? Yes

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: osteoporosis, animal models of osteoporosis & osteoarthritis, tocotrienol, vitamin E

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.
Nicole C. Wright
Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL, USA

The authors evaluated the use of osteoporosis medications in a predominantly Hispanic population. This is important to the field as data is lacking on the use of osteoporosis medications in Hispanics and other people of color. The study was derived from hospital claims, which provides high level of specificity for fractures; however, there were a series of methodologic concerns that are needed to be corrected.

1) The paper subheadings need to be reorganized, particularly when it comes to exposure and outcome variables. I would suggest the following:
   - Ethics statement.
   - Study design and setting - can probably include description of participants here.
   - Fracture identification and respective codes; including position in the record where codes were derived.
   - Medication identification - again which meds and where identified in the record.
   - Covariates of interest.
   - Statistical Analysis.

2) Fracture identification - there are published algorithms for identification that use ICD code, surgical procedure codes, as well as imaging codes (Wright et al., 2019). Consider utilizing these algorithms, particularly for clinical vertebral fractures. This could potentially increase the number of fractures in the population.

3) A flowchart of exclusions is needed to show the reader visually the sample size determination.

4) How good of a surrogate is the "last known reported activity"? If there is data around this, please provide validity estimates. If not, I would reconsider phrasing this as mortality unless you have vital status information.

5) Sentence structure: I would avoid starting sentences with numbers.

6) Tables 1 and 2 could have group comparisons using chi-square test and ANOVA.

7) I would reconsider the shading in figures for those who are printing article in black and white.

References

Is the work clearly and accurately presented and does it cite the current literature?
Partly

Is the study design appropriate and is the work technically sound?
Yes
Are sufficient details of methods and analysis provided to allow replication by others?  
Partly

If applicable, is the statistical analysis and its interpretation appropriate?  
Yes

Are all the source data underlying the results available to ensure full reproducibility?  
No

Are the conclusions drawn adequately supported by the results?  
Yes

**Competing Interests:** No competing interests were disclosed.

**Reviewer Expertise:** Musculoskeletal research; osteoporosis epidemiology; racial disparities in osteoporosis management; outcomes research

I confirm that I have read this submission and believe that I have an appropriate level of expertise to state that I do not consider it to be of an acceptable scientific standard, for reasons outlined above.

---

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com